A new way to target and destroy ovarian cancer cells
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment
This research explores a new combination of materials designed to specifically kill drug-resistant ovarian cancer cells without harming healthy ones.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Carolina at Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11159850 on NIH RePORTER |
What this research studies
Ovarian cancer is often difficult to treat because it can become resistant to many common medications, leading to a high death rate. We are developing a special polymer-metal combination that has shown promise in selectively destroying cancer cells, including those that are drug-resistant. This project aims to understand exactly how this new combination works, make it even more effective at targeting cancer, and test its safety and ability to stop tumor growth.
Who could benefit from this research
Good fit: Future patients who might benefit from this research are those with advanced ovarian cancer, especially if their cancer has become resistant to current treatments.
Not a fit: Patients whose ovarian cancer responds well to existing treatments may not directly benefit from this specific new approach, as it targets drug resistance.
Why it matters
Potential benefit: If successful, this work could lead to a safer and more effective treatment option for women with advanced, drug-resistant ovarian cancer.
How similar studies have performed: This approach uses a novel polymer-metal combination and a unique mechanism to kill cancer cells, making it a new and untested strategy.
Where this research is happening
Columbia, United States
- University of South Carolina at Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Xu, Peisheng — University of South Carolina at Columbia
- Study coordinator: Xu, Peisheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.